ACO REACH & MSSP
Expert articles and analysis related to aco reach & mssp.
AI Summary — Last 30 Days
Over the past 30 days, CMS has advanced the strategic transition from ACO REACH and MSSP toward the forthcoming LEAD (Long-term Enhanced ACO Design) Model, with applications now open for participants and stakeholder attention focused on the model's structural innovations—most notably the elimination of rebasing, expansion of capitation, and introduction of specialist risk-sharing mechanisms. These shifts position LEAD as a next-generation ACO platform, aiming to resolve persistent tensions in risk adjustment, benchmarks, and sustainability while strengthening participation incentives for physician groups and health systems. As ACO REACH prepares for Performance Year 2026 changes and LEAD targets a 2027–2036 timeline, organizations are under pressure to reassess infrastructure, risk appetite, and partnerships to remain competitive in an evolving Medicare value-based care landscape (Wakely: LEAD Model, AHA: CMS seeks applicants for LEAD ACO Model).
Related Articles
Cedar Gate Targets Growing Demand for Value-Based Care ACO Solutions
Cedar Gate Targets Growing Demand for Value-Based Care ACO Solutions TipRanks
Bipartisan bill would cap insulin at $35 per month
Bipartisan bill would cap insulin at $35 per month Becker's Hospital Review
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle Health Affairs
IRA Drug Provisions Linked to Significant Drop in Medicare Medication Nonadherence
New CMS model brings ACO approach to care for kids at high risk
New CMS model brings ACO approach to care for kids at high risk American Medical Association
CVS reaches insulin pricing settlement with FTC
CVS reaches insulin pricing settlement with FTC Health Leaders Media
Innovaccer Highlights Strategy Role in ACO Model Decisions and Value-Based Care
Innovaccer Highlights Strategy Role in ACO Model Decisions and Value-Based Care TipRanks
CVS Caremark, FTC reach settlement in insulin pricing case
CVS Caremark, FTC reach settlement in insulin pricing case Fierce Healthcare
STAT+: FTC strikes proposed deal with CVS over charges its PBM manipulated insulin prices, impeded access
The FTC said the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.
Innovaccer Spotlights Strategic Choices for ACOs in Value-Based Medicare Models
Innovaccer Spotlights Strategic Choices for ACOs in Value-Based Medicare Models TipRanks